Product Program year 2022 Source: CMS Open Payments

BRAC CDx

Device Germline Dna Sequencing Hereditary Cancer And Rearrangement Analysis

Open in the dashboard

General payments

$1,088,217

1,569 payments

Research payments

$0

0 payments

Through program year 2022, $1,088,217 in general payments and $0 in research payments were reported against BRAC CDx (Germline Dna Sequencing Hereditary Cancer And Rearrangement Analysis).

No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.

By program year

2 rows
Year Kind Amount Payments
2022 General $1,085,779 1,524
2021 General $2,438 45

Breakdown

Who paid General payments · program years 2021–2022
  1. Myriad Genetic Laboratories, Inc. $1,088,217 1,569 payments
Top recipients General payments · program year 2022
  1. Childrens Hospital Corporation Teaching hospital · MA $720,492 66% · 4 payments
  2. Ut Md Anderson Cancer Center Teaching hospital · TX $292,286 27% · 7 payments
  3. Sucharu Prakash Medical Oncology · Paris, TX $11,383 1% · 13 payments
  4. Adam Cole Anatomic Pathology & Clinical Pathology · Little Rock, AR $9,241 <1% · 8 payments
  5. Shail Dalal Hematology & Oncology · Palestine, TX $4,470 <1% · 10 payments

The top 5 of the 100 largest recipients; each share is of general payments naming this product in 2022.

The top 25 recipients, free in the app

Specialties paid General payments · program year 2022
  1. Urology $17,889 26% · 387 practitioners
  2. Medical Oncology Internal Medicine $12,038 17% · 17 practitioners
  3. Anatomic Pathology & Clinical Pathology Pathology $10,242 15% · 16 practitioners
  4. Hematology & Oncology Internal Medicine $6,554 9% · 70 practitioners
  5. Radiation Oncology Radiology $6,337 9% · 43 practitioners

The top 5 of 36 specialties; each share is of general payments naming this product to practitioners with a specialty in 2022. Each practitioner is counted under their primary specialty.

The top 25 specialties, free in the app

Where the money went General payments · program year 2022
  1. Massachusetts $720,717 66% · 17 recipients
  2. Texas $313,666 29% · 115 recipients
  3. Arkansas $11,785 1% · 46 recipients
  4. Washington $4,897 <1% · 35 recipients
  5. California $4,766 <1% · 80 recipients

The top 5 of 41 states; each share is of general payments naming this product in 2022 where a state was reported.

The top 25 states, free in the app

1,569 general

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

What you are looking at

Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.

Provenance

Source: CMS Open Payments · through program year 2022

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record